Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
Status:
Suspended
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
A recent study by Plotkin et al. showed that bevacizumab (Avastin) treatment was followed by
clinically meaningful hearing improvement, tumor-volume reduction, or both in some, but not
all, patients with Vestibular Schwannoma (VS) who were at risk for complete hearing loss or
brain-stem compression from growing VS. Because of the promising results in preliminary
studies of Bevacizumab and because of significant experience with the safety of the dosages
proposed in this study, this study will offer a safe treatment for patients with VS.
Therefore, this phase I clinical research trial will test the hypothesis that Bevacizumab can
be safely used by direct intracranial superselective intraarterial infusion up to a dose of
10mg/kg to ultimately enhance survival and hearing function of patients with VS.
Phase:
Phase 1
Details
Lead Sponsor:
Northwell Health
Collaborators:
Feinstein Institute for Medical Research Hofstra North Shore